Clinical Observation of Prednisone Acetate Combined with Leflunomide in the Treatment of IgA Ne-phropathy
10.6039/j.issn.1001-0408.2016.08.35
- VernacularTitle:醋酸泼尼松联合来氟米特治疗IgA肾病的临床观察
- Author:
Dengfeng LI
;
Jinxiang REN
- Publication Type:Journal Article
- Keywords:
Prednisone acetate;
Leflunomide;
IgA nephropathy;
Effectiveness
- From:
China Pharmacy
2016;27(8):1118-1119,1120
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe therapeutic efficacy and safety of prednisone acetate combined with leflunomide in the treatment of IgA nephropathy. METHODS:80 patients with IgA nephropathy were randomly divided into observation group and control group,with 40 cases in each group. Control group was given prednisone acetate 1.0 mg/kg,qd,6 weeks later,decreasing gradually,decreasing to 0.5 mg/kg in 12th week;observation group was additionally given leflunomide 50 mg,qd,3 days later de-creasing to 20 mg. Both groups were given 3 months of treatment. Clinical efficacy,24 h urinary protein quantification,Scr and BUN levels were observed in 2 groups after treatment,and ADR were recorded during treatment. RESULTS:Total effective rate of observation group(95.0%)was significantly higher than that of control group(75.0%),with statistical significance(P<0.05). Af-ter treatment,24 h urinary protein quantification,Scr and BUN levels of observation group were significantly lower than those of control group,with statistical significance(P<0.05). The incidence of ADR in observation group(0)was significantly lower than in control group(7.5%),with statistical significance(P<0.05). CONCLUSIONS:Prednisone acetate combined with leflunomide has significant effect on IgA nephropathy,and will not increase the occurrence of ADR.
